Severe Iron Deficiency Treatment Guidelines

Introduction to Severe Iron Deficiency

For patients with severe iron deficiency, intravenous iron formulations are strongly recommended over intramuscular iron dextran due to superior efficacy, better tolerability, and fewer adverse effects, as suggested by the American Gastroenterological Association and the European Society for Clinical Nutrition and Metabolism 1, 2
Severe iron deficiency, indicated by a ferritin level of 7 ng/mL, requires prompt and effective iron repletion to restore hemoglobin concentrations, normalize red cell indices, and replenish iron stores, according to the National Institute of Diabetes and Digestive and Kidney Diseases 2

Intramuscular iron dextran is associated with painful injections, tissue damage, and unacceptable side effects, making it an obsolete option by current guidelines from the American College of Gastroenterology 3
Intravenous iron formulations are more effective in correcting iron deficiency, better tolerated, and allow for higher single doses with fewer administrations, as recommended by the European Society for Clinical Nutrition and Metabolism 3, 2
Available IV iron formulations include iron sucrose, ferric carboxymaltose, iron dextran, and iron isomaltoside 1000, with varying dosing limits, such as up to 200-300mg per dose for iron sucrose and up to 1000mg per dose for ferric carboxymaltose, as approved by the FDA and recommended by the American Society of Hematology 3, 2, 1

The first-line recommendation for severe iron deficiency is intravenous iron formulation, with ferric carboxymaltose preferred due to its ability to deliver higher doses, lower risk of adverse reactions, and demonstrated efficacy, as suggested by the American College of Cardiology and the European Heart Rhythm Association 1, 2, 5
Dosing considerations include a total dose of 1500mg for patients with hemoglobin 7-10 g/dL and weight <70kg, and 2000mg for patients with hemoglobin 7-10 g/dL and weight ≥70kg, typically administered as 1-2 infusions, as recommended by the National Comprehensive Cancer Network 3, 1, 2

Repeat basic blood tests, including hemoglobin, ferritin, and transferrin saturation, 8-10 weeks after treatment to assess response, as recommended by the American Society of Clinical Oncology and the National Kidney Foundation 1, 2
Target ferritin level >100 ng/mL to ensure adequate iron stores, and consider maintenance therapy if risk factors for recurrent deficiency exist, as suggested by the Kidney Disease: Improving Global Outcomes initiative and the American Journal of Kidney Diseases 6, 7, 1, 2

Test doses are required for iron dextran due to the risk of anaphylactic reactions, and intravenous iron should not be administered in the presence of active infection, as warned by the FDA and the Centers for Disease Control and Prevention 3, 8
Upper limits for therapy should be transferrin saturation above 50% and serum ferritin above 800 μg/L, and avoid iron supplementation in patients with normal or high ferritin values as it is potentially harmful, as recommended by the American Heart Association and the European Society of Cardiology 3, 1